Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Geneius Biotechnology Inc. currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This workload is handled by 1 distinct examiner and 1 distinct art unit. HAM, JIEUN is the busiest examiner, with 1 pending office action.
The presence of 1 distinct art unit suggests that the company's current patent activity is specialized within a specific technical niche. Because the busiest examiner pending count of 1 matches the total pending office actions of 1, the active portfolio is currently under the review of 1 distinct examiner. This concentration means that the outcome of the company's current prosecution depends on the evaluation of this individual. Practitioners should note that with this limited workload, there is no internal baseline for comparing examiner behavior within this specific portfolio. The alignment of the assigned staff and 1 distinct art unit suggests a direct path for the company's current intellectual property efforts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| HAM, JIEUN | 1 | 45.5% | +0.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18038834 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | HAM, JIEUN | — |
| Art Unit | Apps |
|---|---|
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18038834 | ANTIGEN SPECIFIC T CELLS AND METHODS OF MAKING AND USING SAME | HAM, JIEUN | 1643 | §102§103§112 | Non-Final OA | — | Pending | May 25, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGeneius Biotechnology Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jieun Ham has the most, with 1 of Geneius Biotechnology Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
